Appointment follows successful £690k crowdfunding campaign
Quin, a pioneering, female-founded, med-tech start-up, announces the
appointment of John Lister to its executive board. John brings considerable experience to his new role, previously working as general counsel and general manager EMEA at continuous glucose monitor (CGM) producer, Dexcom.
Quin recently closed a £690,000 crowdfunding campaign, as it prepares for launch later this year. As a board member, John will advise Quin on strategy and routes to commercialisation , as it approaches a number of significant milestones.
Quin is a mobile medical app that gives individualised insulin-dosing guidance and creates novel insights to enable personalised medicine for type 1 diabetes. It redefines diabetes management by holistically accounting for the behavioural and physiological factors at play in the daily life of a person with diabetes. The company is preparing to launch its app for trial in June, limited to people who use Dexcom CGMs, before fully releasing the app to individuals using any type of CGM in the UK and Ireland in September.
Quin CEO and Co-Founder, Cyndi Williams said: “John has a wealth of experience in the diabetes technology industry, and we are excited to add his expertise to the board. His knowledge and insight will play a major role in our ambition to help people better understand, and ultimately improve their diabetes management.”
John Lister added: “I am excited to be joining the board and to become part of Quin’s admirable mission to help people living with type 1 diabetes achieve better health outcomes and a higher quality of life. Through my previous experience, I understand the challenges faced by individuals on a daily basis and am proud to be part of the movement to make type 1 diabetes more manageable.”
Also joining Quin, as part of the Clinical Advisory Board, are Dr Sankalpa Neupane and Dr Nicola Neary. Both are highly respected diabetologists from Norfolk and Norwich University Hospitals and St George’s University Hospitals respectively. Their vast experience and passion for making life diabetes easier through technology will be welcomed at Quin.
Since starting up Quin has raised £2.6 million in grants and angel funding, recruited hundreds of beta testers, and launched its ML research partnership with the University of Bristol. Accolades include winning the Diabetes Center Berne Start-up stage competition, being selected for the Apple Entrepreneur Camp, receiving ISO 13485 certification, and being used as a case study by government-funding body, Innovate UK. Quin has also filed two patents and launched the beta programme in five additional European countries.
Media release contact details:
+44 (0)780 813 1960
About Quin Technology LTD
Quin is a mobile medical app and biodata company that’s pioneering consumer-led breakthroughs in insulin-treated diabetes. Quin’s intellectual property and ML algorithms go far beyond existing medical knowledge and models. They aim to make living with insulin-treated diabetes easier by relieving the self-care decision-making load and advancing diabetes research.